Ultrasound technology developer Misonix of Farmingdale, NY, has sold the rights to its high-intensity focused ultrasound (HIFU) technology to US HIFU of Charlotte, NC.
Misonix had previously obtained the HIFU technology and other HIFU-related assets from Focus Surgery (FSI), a wholly owned subsidiary of US HIFU. Misonix will receive up to $5.8 million from the transaction and will be paid for its inventory of new SB500 systems and inventory associated with manufacturing the SB500.
The rights include a manufacturing agreement for the SB500 console, a distribution agreement for the sale of the SB500 for prostate cancer in Europe and the Russian Federation, and licenses to develop products using FSI technology for kidney, liver, and breast tissue.
Misonix also will sell all of the SB500 systems currently used in Europe for fee-per-use procedures.
Misonix will retain its rights to HIFU-related intellectual property and development assets recently purchased from ProRhythm of Ronkonkoma, NY. The intellectual property includes the development of new transducers and lenses for the treatment of tissue using HIFU.
Related Reading
Misonix enters Scandinavia distribution pact, February 4, 2010
Misonix inks Chile distribution deal, January 12, 2010
Misonix expands in Mexico, January 8, 2010
Misonix sells Sonora, October 5, 2009
Sonora nets 8th patent, September 1, 2009
Copyright © 2010 AuntMinnie.com
![Examples of ultrasound findings and techniques. (A) Images in a 39-year-old male patient with a mass in the left thigh. The mass is heterogeneous on the B-mode US image (compared with the patient in D) and showed increased microvascularity (superb microvascular imaging [SMI]) and shear-wave elastography (SWE) values. Undifferentiated pleomorphic sarcoma was diagnosed at biopsy (with pleomorphic rhabdomyosarcoma in surgical specimen). (B) Images in an 18-year-old male patient with a mass in the left leg. The mass is hypoechoic on the B-mode image, with no other findings suggestive of malignancy. The lesion is in contact with the cortex of the tibia, which is slightly irregular. CT revealed a doubtful anteromedial tibial erosion. The microvascular study demonstrated high vascularization, suggestive of malignancy. Periosteal Ewing sarcoma was diagnosed with both histologic and immunohistochemical confirmation. (C) Images in a 69-year-old female patient with a lump growing on the outside of the left leg. Multiple SWE examinations were performed (please note the high values obtained in the measurements, whereas the color map highlights the stiffness relative to adjacent tissues). SMI showed areas of increased vascularization to target for sampling. Undifferentiated spindle cell sarcoma was diagnosed at biopsy, with residual leiomyosarcoma in the surgical specimen after neoadjuvant therapy. (D) Images in a 56-year-old female patient with a mass in the right thigh. The mass is heterogeneous at both B-mode ultrasound (similar to patient A) and MRI (coronal T2-weighted spectral attenuated inversion recovery [SPAIR]; T1-weighted pre-contrast and postcontrast imaging), which even shows uptake after the administration of paramagnetic contrast material, which is traditionally suggestive of malignancy. Low values at SMI and elastography are suggestive of benignity. Spindle cell lipoma was diagnosed at biopsy, with atypical spindle cell lipomatous tumor in the surgical specimen.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/08/images-radiol250278fig2.APCFLSvX6p.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)